Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Historically in biotech your strategy is the right one and I can see why you would adopt it.
My point is due to FOMO I expect little or no retracement.
I respectfully disagree.
If the share price were to retract to $7 as you postulate I would literally
sell every other stock in my Roths to buy AVXL and I'd have plenty of company.
Not because they have a crackerjack CEO or a fab R&D department but because they have unique situation.
They're running trials for multiple indications using THE EXACT SAME DRUG.
This is unheard of and would be a de risking element that would and could not be ignored.
Charlie Munger, one of my thought process heroes says "you only get a few fat pitches in life and when you recognize one you better go big enough to move the needle".
PDD approval would compel me to act on that advice.
In Spain, mid year is generally considered to be July 21st, one month after the summer solstice.
Thanks. What's your take on this event?
Thanks. what's your take on this event?
Despite scouring the web I can't find this newest financing info.
Could you help me out?
I think the lack of a reply speaks to the strength of your arguments.
Interesting mitochondria article.
Envisioning a daily A2-73 pill followed by a visit to the red light district.
https://www.cnn.com/2020/06/30/health/declining-eyesight-red-light-scn-wellness/index.html
It strikes me this is downstream from where A2-73 does its work although I was hoping falconer might weigh in on as to whether A2-73 might also help in the cleansing process.
Perhaps helping clear out the icky stuff that may have accumulated prior to administering A2-73?
Related, if not pertinent.
https://newatlas.com/medical/yale-video-brain-dead-neurons/
Maybe one of the recent hires said "Y'know, Chris...."
That was my initial thought.
I may have missed this revelation earlier but this statement would seems to be the big news:
" We feel that we can take Rett Syndrome and Parkinson’s treatment to market ".
Didn't we previously think we could only do Rett alone?
Agreed.
One question that comes to mind is when did they apply for Regulatory Approval in these countries.
If it was at the trials inception I would regard it as "well done" but would find the approval a neutral event.
A few weeks ago it was posted that Anavex hadn't sold any shares over a recent 3 month period.
Is this a true statement? Thanks in advance.
What would happen if a quarantine interrupted a drug trial?
Good article highlighting the power of AI regarding drugs.
https://www.theguardian.com/society/2020/feb/20/antibiotic-that-kills-drug-resistant-bacteria-discovered-through-ai
I've a question.
Not sure how to phrase it but I'm sure you'll get the idea.
Let's say I just finished one of the 3 trials and am entering the extension.
Will the company be able poke me, prod me, draw fluids, play dosing games and test me at will?Are they privy to my baseline numbers established prior to dosing?
The reason I ask all this is I'm wondering if, patient by patient coming off the trials, couldn't they ascertain exactly how the trials are going by clever analysis?
He does and has quoted falconer( and perhaps others) in the past.
I subscribe off and on to his service (BI Research).
This board knows as much as he does but hats off to him for attending the conference calls and asking pertinent questions.
[In a note Monday, Cantor Fitzgerald analyst Louise Chen wrote that the news on the study’s failure wasn’t surprising, “given the small study size, patient population and novel trial design.”]
Probably how Anavex's trials are viewed.
Thanks.
Couple of questions as I haven't been following AVXL as closely as I used to.
1) Is the Ph2a Peer Review paper by 10/2020 the same one that was promised for last year?
2) A couple months ago the trial timelines were pushed back.
A Rett(readout?) was forecast for 3/31/2020. Is that still valid?
Couldn't tell from the conference call as there are multiple Rett trials ongoing.
Could it be possible that A2-73 would be harmful to the purpose these particular mitochondria serve?
Do you think it's possible that Anavex allotted a finite amount of personal/cash for recruiting and now that PDD is fully enrolled AD gets expanded?
Does a fast track designation improve the likelihood a drug might be approved off Ph2 trial results?
Looks like BP is in the crosshairs on multiple fronts.
https://www.statnews.com/2020/01/12/venture-capitalist-alexis-borisy-bring-down-drug-prices/
I take some comfort in the institutional ownership.
Were they to begin heading for the exits...
But this wasn't the only path.
We could have partnered/sold for a modest amount of money, perhaps a Japanese company as Xena suggests, who wouldn't have hid it under a barrel but instead would have taken it to the bank.
With the clout and deep pockets a BP has we might be on the cusp of a Ph2 double blind placebo- based approval.
As is often the case, it's about the pursuit of money.
Obviously not a cure but an interesting story nonetheless.
https://www.mprnews.org/story/2019/12/24/npr-her-mom-was-lost-in-dementias-fog-singing-christmas-carols-brought-her-back
In the past you've you've mentioned the potential veterinary benefits with the possibility of reducing the massive amount of antibiotics used.
Could you elaborate a bit?
My guess is you're inferring a well fuctioning body will prevent the infection(s) in the first place?
https://news.yahoo.com/crisis-looms-antibiotics-drugmakers-bankrupt-195938339.html
FYI: custodial Roth IRA's
Recently opened up one for my niece.
Easy enough to do but was surprised Charles Schwab was the lone broker I recognized to offer one.
On the plus side, no trading fee is huge in a small account like this.
Don't forget the child must have earned income.
And yes, in addition to some blue chip dividend paying stocks she is officially an Anavex shareholder.
Moot point I'd imagine.
It does seem to me team Anavex did what it could with what it had.
I'll take a shot.
"And I understand that we have reached the highest enrollment in Australia ever in the history of Alzheimer’s study enrollment in terms of numbers recruited for Alzheimer’s patients"?
In the interest of clarity, I don't seem to be able to distinguish my arse from a hole in the ground.
Why not poor planning?
If you look at it objectively, most of our faith in the management side of Anavex is of the blind kind.
Interesting article, not sure how pertinent it is to Anavex.
https://news.berkeley.edu/2019/12/04/drugs-that-quell-brain-inflammation-reverse-dementia/
Meant to be a list of the ones we know about, dwarfed by the goings on we're unaware of.
Enron, Bernie Madoff, Volkswagon emissions scandal, mutual funds caught trading after hours, Russian election meddling, opioids dispensed with gay abandon... everywhere I look I'm reminded money talks.
It might be naive of us to think the deep pocketed BP isn't doing anything and everything they can think of to slow us down.
Falconer recently said introducing a new class of drugs is no small task and would take time.
With billions of dollars at stake we should probably expect headwinds too.
It's still an unnecessary use of funds and attracts shorts like flies.
And you can never be sure how some wacko judge might rule.
Lawsuit avoidance.